EGFR/VEGFR2 inhibitors (ProQinase/Federal University of Rio de Janeiro)

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameEGFR/VEGFR2 inhibitors (ProQinase/Federal University of Rio de Janeiro)
Drug Alias NameMLBS-42
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsVascular endothelial growth factor receptor 2Epidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyBrazil
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesReaction Biology Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesReaction Biology CorpUniversidade Federal Do Rio De Janeiro
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A